Don't want ads? Subscribe or login now.

Fenwick, WilmerHale Steer $285M Mersana Take-Private Deal

By Jade Martinez-Pogue · November 13, 2025, 5:52 PM EST

Pediatric cancer-focused biopharmaceutical company Day One Biopharmaceuticals, led by Fenwick & West LLP, announced plans Thursday to acquire clinical-stage biopharmaceutical company Mersana Therapeutics Inc., advised by WilmerHale, in a take-private deal...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Jade

October 14, 2025
Ōura Valuation Soars To $11B After $900M Financing Round
October 02, 2025
Singaporean Biotech To Go Public Via $1.5B SPAC Merger
October 01, 2025
Weil, Morgan Lewis Steer Up To $900M Biopharma Purchase
September 23, 2025
AI Health Benefits Platform Secures $400M In New Funding
September 18, 2025
Group Of US Investors To Buy TikTok, Plus More Rumors
September 16, 2025
VarmX Partners With Biotech CSL In Deal Worth Up To $2.2B
September 02, 2025
Evernorth Health Plugs $3.5B Into Shields Health Solutions
August 25, 2025
AbbVie Nabs Depression Drug From Gilgamesh In $1.2B Deal
August 19, 2025
Sleep Fitness Biz Eight Sleep Raises $100M In VC Funding
August 12, 2025
Bayer Bets $1.3B On Kumquat Cancer Drug Candidate

Fenwick, WilmerHale Steer $285M Mersana Take-Private Deal

Related Sections

Recent Articles By Jade